GTBP
GT Biopharma, Inc.
There isn't enough reported data to score GTBP yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
GTBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Under pressure |
GTBP's profitability and balance sheet are currently under pressure. There isn't enough data to rate its revenue and cash flow.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
GTBP PE Valuation
GTBP has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
GTBP Forward outlook
There aren't enough analyst estimates for GTBP to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
GTBP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$295.25 | -$110.75 |
| Q2 2025 | -$359.50 | -$168.25 |
| Q1 2025 | -$140.75 | +$33.75 |
| Q4 2024 | -$173.50 | -$32.50 |
| Q3 2024 | -$184.50 | +$36.92 |
| Q2 2024 | -$191.25 | +$150.17 |
| Q1 2024 | -$174.50 | +$204.42 |
| Q4 2023 | -$141.00 | +$357.92 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 260% for GTBP versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
GTBP Quarterly Revenue
GTBP and UNH do not have enough comparable growth data to identify a winner.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
GTBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.3M | -$1.2M |
| Q1 2026 | -$2.5M | -$266K |
| Q4 2025 | -$4M | -$1.6M |
| Q3 2025 | -$3.7M | -$940K |
| Q2 2025 | -$3M | +$522K |
| Q1 2025 | -$2.2M | +$2M |
| Q4 2024 | -$2.5M | -$421K |
| Q3 2024 | -$2.7M | -$773K |
GTBP has burned cash in almost every quarter: −$14M over the past year, against −$10M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over GTBP on cash generation, producing positive trailing cash flow while its opponent burns cash.
GTBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +28% | +342K shares |
| 1 year | +1555% | +1.5M shares |
| 3 years | +2880% | +1.5M shares |
| 5 years | +7071% | +1.5M shares |
| Available history | +33569% | +1.5M shares |
GTBP has 2M diluted shares, up 1555% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over GTBP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
GTBP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | 3.8x | Elevated |
GTBP's net debt is about 3.8 years of its operating earnings (EBITDA).
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
GTBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 3.4 | Oversold |
GTBP's weekly RSI is 33 (neutral) and its Stochastic is 3 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
GTBP PE vs Healthcare Sector
GTBP has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
GTBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.72 | 33% below |
| 20 week MA | $7.22 | 47% below |
| 50 week MA | $10.7 | 64% below |
| 100 week MA | $29.2 | 87% below |
| 200 week MA | $108.4 | 96% below |
GTBP is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over GTBP on trend strength, trading above more of its moving averages.
GTBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,236.8 | $7,356.8 | +495% |
| 2021 | $7,356.8 | $2,790.0 | -62% |
| 2022 | $2,790.0 | $817.5 | -71% |
| 2023 | $817.5 | $191.3 | -77% |
| 2024 | $191.3 | $75.5 | -61% |
| 2025 | $75.5 | $20.8 | -72% |
| 2026 YTD | $20.8 | $3.84 | -82% |
GTBP has finished five years in a row lower, and it's down 82% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over GTBP on returns for 2026, with the stronger performance.